Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MRKR Marker Therapeutics
0.369
-0.005-1.23%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
0 0 166.01% 1.24M 1.24M
Operating revenue
-- 0 -- 0 166.01% 1.24M -- 1.24M
Cost of revenue
Gross profit
Operating expense
-14.93% 9.28M 11.54% 9.79M 38.73% 40.72M 29.35% 11.01M
Selling and administrative expenses
-1.24% 3.52M 18.96% 3.73M 23.42% 12.92M 18.36% 2.99M
-General and administrative expense
-1.24% 3.52M 18.96% 3.73M 23.42% 12.92M 18.36% 2.99M
Research and development costs
-10.81% 6.56M 24.51% 7.03M 47.21% 27.79M 33.99% 8.02M
Other operating expenses
-- -790.51K -- -964.32K -- -- -- --
Operating profit
14.93% -9.28M -11.54% -9.79M -36.67% -39.48M -14.76% -9.76M
Net non-operating interest income expense
1389.22% 35.79K 102.8% 3.12K -96.17% 5.7K -22.42% 969
Non-operating interest income
1389.22% 35.79K 102.8% 3.12K -96.17% 5.7K -22.42% 969
Other net income (expense)
-118.88K -7863.15% -2.41M 0
Special income (charges)
-- -- -- -118.88K -- -- -- --
-Less:Other special charges
-- -- -- 118.88K -- -- -- --
Other non- operating income (expenses)
-- -- -- -- -- -2.41M -- 0
Income before tax
15.24% -9.24M -12.88% -9.91M -45.89% -41.88M -14.76% -9.76M
Income tax
Net income
15.24% -9.24M -12.88% -9.91M -45.89% -41.88M -14.76% -9.76M
Net income continuous Operations
15.24% -9.24M -12.88% -9.91M -45.89% -41.88M -14.76% -9.76M
Minority interest income
Net income attributable to the parent company
15.24% -9.24M -12.88% -9.91M -45.89% -41.88M -14.76% -9.76M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
15.24% -9.24M -12.88% -9.91M -45.89% -41.88M -14.76% -9.76M
Basic earnings per share
15.38% -0.11 25% -0.12 9.84% -0.55 33.33% -0.12
Diluted earnings per share
15.38% -0.11 25% -0.12 9.84% -0.55 33.33% -0.12
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
CEO: Hoang MBA, Peter L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top